Bonenkamp J J, van de Velde C J, Kampschöer G H, Hermans J, Hermanek P, Bemelmans M, Gouma D J, Sasako M, Maruyama K
Department of Surgery, University Hospital, Leiden, The Netherlands.
World J Surg. 1993 May-Jun;17(3):410-4; discussion 415. doi: 10.1007/BF01658714.
As a result of Japanese reports of improved survival of gastric cancer patients after extended lymph node dissection, a study was undertaken to evaluate factors that might influence these results. The influence of staging was evaluated by stratifying 1085 patients of the National Cancer Center of Japan and grouping them according to the three commonly used systems; UICC's old and new TNM systems (fourth edition) and the system of the Japanese Research Society for the study of Gastric Cancer (JRSGC). No survival difference was found between the stages of the three systems, except for stage II, where the new TNM and the JRSGC differed (p < 0.05). In a second analysis, the incidence of the most important prognostic factors for advanced gastric cancer was compared among three institutions: the National Cancer Center Tokyo, Japan (NCC), the University Hospital Erlangen, Germany (UHE) and the University Hospital Maastricht in The Netherlands (UHM). Japanese patients were on average 3 years younger than the German patients and 8 years younger than the Dutch patients, and had a higher proportion of advanced (T4) carcinomas. Male-female distribution, histology, and lymph node invasion were comparable in the three groups. From these data a rather worse prognosis for Japanese advanced gastric cancer patients could be expected. However, the observed 5-year survival rates show a marked advantage for the Japanese patients: 57% (NCC) versus 34% (UHE) and 31% (UHM). The survival difference for stage II patients between the new TNM and the JRSGC staging systems is not sufficient to explain this advantage. This result underlines the importance of the Japanese therapeutic approach.(ABSTRACT TRUNCATED AT 250 WORDS)
由于日本有报道称扩大淋巴结清扫术后胃癌患者的生存率有所提高,因此开展了一项研究以评估可能影响这些结果的因素。通过对日本国立癌症中心的1085例患者进行分层,并根据三种常用系统进行分组,来评估分期的影响;这三种系统分别是国际抗癌联盟(UICC)的旧版和新版TNM系统(第四版)以及日本胃癌研究学会(JRSGC)的系统。除了II期,三种系统的各分期之间未发现生存差异,在II期,新版TNM系统和JRSGC系统存在差异(p<0.05)。在第二项分析中,比较了三个机构中晚期胃癌最重要预后因素的发生率:日本东京国立癌症中心(NCC)、德国埃尔朗根大学医院(UHE)和荷兰马斯特里赫特大学医院(UHM)。日本患者的平均年龄比德国患者小3岁,比荷兰患者小8岁,且晚期(T4)癌的比例更高。三组的男女分布、组织学和淋巴结侵犯情况具有可比性。根据这些数据,预计日本晚期胃癌患者的预后会更差。然而,观察到的5年生存率显示日本患者具有显著优势:57%(NCC),而德国埃尔朗根大学医院为34%,荷兰马斯特里赫特大学医院为31%。新版TNM系统和JRSGC分期系统在II期患者中的生存差异不足以解释这一优势。这一结果强调了日本治疗方法的重要性。(摘要截选至250字)